CatLane 15 states, mostly led by Democrats, are suing the Trump administration, seeking judicial intervention to reverse recent changes the Centers for Disease Control and Prevention (CDC) introduced to the U.S. childhood vaccine schedule. The California and Arizona attorneys general announced that 14 states and Pennsylvania Governor Josh Shapiro teamed up to file the lawsuit on Tuesday, which cha...
CatLane 15 states, mostly led by Democrats, are suing the Trump administration, seeking judicial intervention to reverse recent changes the Centers for Disease Control and Prevention (CDC) introduced to the U.S. childhood vaccine schedule. The California and Arizona attorneys general announced that 14 states and Pennsylvania Governor Josh Shapiro teamed up to file the lawsuit on Tuesday, which challenges the CDC’s move to recommend fewer shots for most American children earlier this year. “Undermining confidence in vaccines will lead to lower vaccination rates and more infectious disease,” California Attorney General Rob Bonta said in a statement. “It will also drive up costs for states, including increased Medicaid spending and new expenses to combat misinformation and revise public health guidance.” In addition to the California and Arizona attorneys general, plaintiffs in the suit include AGs in Colorado, Connecticut, Delaware, Maine, Maryland, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, and Wisconsin, as well as the governor of Pennsylvania. The lawsuit filed in a Northern California federal court named the U.S. Department of Health and Human Services and Health Secretary Robert F. Kennedy Jr. as defendants. It also named the CDC and its acting director, Dr. Jay Bhattacharya. The lawsuit also challenges RFK Jr.'s decision to dismiss all members of the CDC’s Advisory Committee on Immunization Practices (ACIP) last year and replace them with his handpicked experts, some of whom have a history of criticizing messenger RNA-based COVID-19 shots. The case is similar to another lawsuit filed by some of the leading medical groups, including the American Academy of Pediatrics and the American Public Health Association, against the Trump administration in a federal court in Massachusetts earlier this month. Dear readers, we recognize that politics often intersect with the financial news of the day, so we invite you to click here to join the separate...
M. Suhail/iStock Editorial via Getty Images Dine Brands Global ( DIN ) fell in early trading on Wednesday after reporting Q4 revenue short of the consensus estimate of analysts. Revenue was up 6.3% year over year to $217.6M vs. $225.7M consensus. The revenue increase in Q4 was primarily driven by higher company-owned restaurant sales, mainly attributable to the increase in the number and timing of...
M. Suhail/iStock Editorial via Getty Images Dine Brands Global ( DIN ) fell in early trading on Wednesday after reporting Q4 revenue short of the consensus estimate of analysts. Revenue was up 6.3% year over year to $217.6M vs. $225.7M consensus. The revenue increase in Q4 was primarily driven by higher company-owned restaurant sales, mainly attributable to the increase in the number and timing of when the company acquired Applebee’s and IHOP restaurants from franchisees, offset by a decrease in franchise revenue due to a decrease in the number of franchise restaurants after the acquisition of franchised Applebee’s and IHOP restaurants. Applebee's year-over-year comparable domestic same-restaurant sales decreased 0.4% in Q4, while IHOP's domestic comparable same-restaurant sales increased 0.3%. Earnings per share of $1.46 topped the consensus mark of $1.06. Looking ahead, the restaurant company sees Applebee’s domestic system-wide comparable same-restaurant sales performance to range between 0% and 2%, and IHOP’s domestic system-wide comparable same-restaurant sales performance to range between 0% and 2%. Consolidated adjusted EBITDA is expected to range between approximately $220M and $230M. "Our 2026 guidance reflects continued targeted investments in growth initiatives that are supported by improving trends across both our franchise business and our company-owned portfolio, and we will continue to focus on efficiently deploying capital towards projects with high return on investment," highlighted CFO Vance Chang. Shares of Dine Brands Global ( DIN ) were down 2.1% in premarket trading. More on Dine Brands Global Dine Brands: The Dual-Branded Catalyst Is Real, But Timing Now Matters (Rating Downgrade) Dine Brands Global, Inc. (DIN) Presents at KeyBanc Capital Markets Consumer Conference 2025 Transcript Dine Brands Global, Inc. (DIN) Presents at Barclays 11th Annual Eat, Sleep, Play, Shop Conference 2025 Transcript Dine Brands Global Q4 2025 Earnings Preview Seekin...
piranka/E+ via Getty Images Overview Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025. Data by YCharts The company markets ANKTIVA (with BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer [NMIBC] with carcinoma in situ [CIS] with or without papillary tumors. While ANKTIVA has struggled out the gate—mainly due to BCG...
piranka/E+ via Getty Images Overview Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025. Data by YCharts The company markets ANKTIVA (with BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer [NMIBC] with carcinoma in situ [CIS] with or without papillary tumors. While ANKTIVA has struggled out the gate—mainly due to BCG shortages—I have always acknowledged its blockbuster potential in this indication. The problem for me has been ImmunityBio’s high cash burn—related to testing ANKTIVA in all kinds of indications outside of bladder cancer—and its valuation that seemed to already account for ANKTIVA in BCG-unresponsive NMIBC. The company’s recent rally—which began in January—has been sparked by a flurry of headlines. The article that follows takes another look at ANKTIVA in its currently FDA-approved indication—to establish a “floor” in ImmunityBio’s valuation—and evaluates whether or not recent developments support the company’s sky-high ~$10 billion enterprise value. Recent Developments ImmunityBio’s rally appears to have begun after reporting Phase 2b/3 NSCLC data on January 13. The press release features a few different data points from two different trials. The most touted data point was that “responders” (those with higher lymphocyte counts) lived longer than “non-responders.” In my opinion, this is kind of “stating the obvious.” This doesn’t necessarily prove that ANKTIVA caused them to live longer. It just supports that patients who are already healthier—or have more robust immune systems—respond better to treatment and naturally live longer regardless of the drug. ImmunityBio also emphasized Absolute Lymphocyte Count—or ALC—as a “key biological endpoint.” But this is not a survival metric like OS or PFS. And stimulating ALC alone is not guaranteed to translate into statistically significant survival improvements. When the company does cite OS, it is against “historical standard of c...
Tommy Schaefer released early from 18-year sentence for 2014 murder of Sheila von Wiese-Mack during luxury holiday Indonesia has freed and deported a US man after he spent 11 years in prison for the premeditated murder of his then girlfriend’s mother on the tourist island of Bali. Tommy Schaefer was sentenced to 18 years in prison for the 2014 murder of Sheila von Wiese-Mack, the mother of Heather...
Tommy Schaefer released early from 18-year sentence for 2014 murder of Sheila von Wiese-Mack during luxury holiday Indonesia has freed and deported a US man after he spent 11 years in prison for the premeditated murder of his then girlfriend’s mother on the tourist island of Bali. Tommy Schaefer was sentenced to 18 years in prison for the 2014 murder of Sheila von Wiese-Mack, the mother of Heather Mack, during a luxury holiday in a case that became known as the Bali suitcase murder. Continue reading...
Acadia Healthcare press release ( ACHC ): Q4 Non-GAAP EPS of $0.07 beats by $0.06 . Revenue of $821.5M (+6.1% Y/Y) beats by $21.37M . Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3%. Adjusted EBITDA was $99.8 million, compared with $153.1 million in the prior-year period ...
Acadia Healthcare press release ( ACHC ): Q4 Non-GAAP EPS of $0.07 beats by $0.06 . Revenue of $821.5M (+6.1% Y/Y) beats by $21.37M . Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3%. Adjusted EBITDA was $99.8 million, compared with $153.1 million in the prior-year period and at the upper end of the Company’s implied fourth-quarter guidance range. Added 181 newly licensed beds during the fourth quarter, including 37 beds to existing facilities and 144 beds from new facilities opened in the fourth quarter. Full Year 2026 Financial Guidance Revenue of $3.37 to $3.45 billion Adjusted EBITDA of $575 to $610 million Adjusted earnings per diluted share of $1.30 to $1.55 (FY EPS consensus is $1.71; FY Revenue consensus is $3.40B). More on Acadia Healthcare The Bottom Fishing Club - Acadia Healthcare: Huge Short Squeeze Potential, Reversing Momentum Acadia Healthcare Company, Inc. (ACHC) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Acadia Healthcare Company, Inc. (ACHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Acadia Healthcare Q4 2025 Earnings Preview Acadia Healthcare rises as David Einhorn touts the stock
Lilia Valutyte was attacked by Deividas Skebas, 26, in Boston in July 2022 while playing outside her mother’s shop A man who murdered a nine-year-old girl by stabbing her in the heart while she played with a hula hoop in the street has been jailed for life with a minimum term of 25 years. Lilia Valutyte was attacked by Deividas Skebas, 26, in the town centre of Boston, Lincolnshire, on 28 July 202...
Lilia Valutyte was attacked by Deividas Skebas, 26, in Boston in July 2022 while playing outside her mother’s shop A man who murdered a nine-year-old girl by stabbing her in the heart while she played with a hula hoop in the street has been jailed for life with a minimum term of 25 years. Lilia Valutyte was attacked by Deividas Skebas, 26, in the town centre of Boston, Lincolnshire, on 28 July 2022 while she was playing outside her mother’s embroidery shop. Continue reading...
Hippo Holdings press release ( HIPO ): Q4 Non-GAAP EPS of $0.67. Revenue of $120.4M (+18.0% Y/Y). Gross Written Premium increased 40% to $288 million over 4Q24 Net Written Premium increased 23% to $97 million over 4Q24 Net Income attributable to Hippo of $6 million compared to $44 million in 4Q24 Adjusted Net Income attributable to Hippo of $18 million, a 20% increase over 4Q24 Net Loss Ratio impr...
Hippo Holdings press release ( HIPO ): Q4 Non-GAAP EPS of $0.67. Revenue of $120.4M (+18.0% Y/Y). Gross Written Premium increased 40% to $288 million over 4Q24 Net Written Premium increased 23% to $97 million over 4Q24 Net Income attributable to Hippo of $6 million compared to $44 million in 4Q24 Adjusted Net Income attributable to Hippo of $18 million, a 20% increase over 4Q24 Net Loss Ratio improved 12 percentage points to 46% compared to 4Q24 Combined Ratio improved 8 percentage points to 99% compared to 4Q24 More on Hippo Holdings Seeking Alpha’s Quant Rating on Hippo Holdings Historical earnings data for Hippo Holdings Financial information for Hippo Holdings
Moussa81/iStock via Getty Images Newmont ( NEM ) will spend ~$800M on Argentina's Cerro Negro mine, the country's economy minister said late Tuesday, according to Reuters. The investment will be used to restart and expand the Cerro Negro Expansion 1 project, which aims to extend the mine's operational life beyond 2035. "This investment aims to strengthen the company's operational safet...
Moussa81/iStock via Getty Images Newmont ( NEM ) will spend ~$800M on Argentina's Cerro Negro mine, the country's economy minister said late Tuesday, according to Reuters. The investment will be used to restart and expand the Cerro Negro Expansion 1 project, which aims to extend the mine's operational life beyond 2035. "This investment aims to strengthen the company's operational safety, boost employment, and promote regional development," Economy Minister Caputo wrote in a post on X. Cerro Negro produced 278K oz of gold in 2025, according to Newmont's ( NEM ) website. More on Newmont Newmont Is A 'Show Me' Story For The Rest Of 2026 Newmont: Gold Is Too Hot To Handle - Mixed Return Prospects Assessing Newmont Corporation's Gold Bet - Lower Risk, Limited Asymmetry
Christophe Leribault, most recently Versailles director, will be tasked with improving security and ‘restoring climate of trust’ France has appointed Christophe Leribault as the new head of the Louvre, bringing in the director of the Palace of Versailles to turn around the world’s most-visited museum after a humiliating jewellery heist and staff strikes. Leribault, who was chosen by the French pre...
Christophe Leribault, most recently Versailles director, will be tasked with improving security and ‘restoring climate of trust’ France has appointed Christophe Leribault as the new head of the Louvre, bringing in the director of the Palace of Versailles to turn around the world’s most-visited museum after a humiliating jewellery heist and staff strikes. Leribault, who was chosen by the French president, Emmanuel Macron, will succeed Laurence des Cars, who resigned on Tuesday . Continue reading...
Ironwood Pharmaceuticals press release ( IRWD ): Q4 Non-GAAP EPS of -$0.01 misses by $0.02 . Revenue of $47.71M (-47.3% Y/Y) misses by $3.22M . 2026 Guidance (February 2026) U.S. LINZESS Net Sales $1.125 - $1.175 billion Driven by improved net price and low-single digit percentage demand growth Total Revenue 1 $450 - $475 million (vs. consensus of $410.5M) Adjusted EBITDA 2 >$300 million Click to ...
Ironwood Pharmaceuticals press release ( IRWD ): Q4 Non-GAAP EPS of -$0.01 misses by $0.02 . Revenue of $47.71M (-47.3% Y/Y) misses by $3.22M . 2026 Guidance (February 2026) U.S. LINZESS Net Sales $1.125 - $1.175 billion Driven by improved net price and low-single digit percentage demand growth Total Revenue 1 $450 - $475 million (vs. consensus of $410.5M) Adjusted EBITDA 2 >$300 million Click to enlarge
Welcome to our guide to the commodities driving the global economy. Today, Canadian energy reporter Robert Tuttle explores the potential revival of the Keystone XL pipeline project. One of the most controversial US energy projects, long thought to be dead and buried, might be coming back to life. The Keystone XL pipeline, a totemic project to bring more Canadian crude to the US Gulf Coast, was can...
Welcome to our guide to the commodities driving the global economy. Today, Canadian energy reporter Robert Tuttle explores the potential revival of the Keystone XL pipeline project. One of the most controversial US energy projects, long thought to be dead and buried, might be coming back to life. The Keystone XL pipeline, a totemic project to bring more Canadian crude to the US Gulf Coast, was canceled by President Joe Biden on his first day in office. Yet five years later, there are signs of revival. Bridger Pipeline, a private US company, filed an application last month with Montana regulators to build a 550,000-barrel-a-day conduit to move Canadian crude through the state into Wyoming. The new project would start near the spot where Keystone XL was supposed to cross into Canada and follow much of the originally planned route. Meanwhile, north of the border, South Bow Corp., the company spun off from Keystone XL developer TC Energy Corp., is considering how to use existing infrastructure to boost exports to the US. Neither company is saying so, but this looks like a quiet revival of Keystone XL, in spirit if not in name. If that turns out to be the case, it would be significant for at least two reasons. First, a resurrection of Keystone XL, even in reduced form and under a different name, would be a win for President Donald Trump, who has called for the project to resume. Trump isn’t the only leader seeking to pivot from his predecessor’s energy legacy. Canadian Prime Minister Mark Carney has pushed to build more pipelines and raised the prospect of a Keystone XL comeback during a meeting at the White House last year. Building more capacity could be politically beneficial for both leaders. Second, even a partial revival of Keystone XL could make it a lightning rod for protests once again, especially as Biden cited climate goals as he revoked the project’s permit back in 2021. A Keystone XL comeback would still face major obstacles. Much of the steel laid in the gr...